A Phase 3 interventional study of Meningococcal C conjugate vaccine in Prevention of Meningococcal Infection, sponsored by Novartis Vaccines. Completed at 2 sites in 2 countries. Open to participants aged 7 Weeks to 16 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-02-08.
Sponsored by Novartis Vaccines · Phase 3, Interventional, and Prevention
Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in healthy children
The aim of this study is to investigate the immunogenicity offered by MenCC vaccine when administered in different schedules at different years of life: 2 doses in the first year of life given 2 months apart (at 2 and 4 months of age), with a booster in the second year of life, or 1 dose in the first year of life (at 2 or 6 months of age), with a booster in the second year of life, or only 1 dose in the second year of life.
219 studies on the registry are indexed under Meningococcal Infections; 6 are open to participants now.
This study's enrollment of 257 is below the median of 450 across 190 interventional studies indexed under Meningococcal Infections.
Browse Meningococcal Infections studies →Novartis Vaccines is the lead sponsor of 161 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Biological: Meningococcal C conjugate vaccine
Biological: Meningococcal C conjugate vaccine
Biological: Meningococcal C conjugate vaccine
Biological: Meningococcal C conjugate vaccine
Meningococcal conjugate vaccine, active comparator. Groups 1 to 3 were given a booster dose in the second year of life at 12-16 months of age
Demonstration of non-inferiority of memory antibody response after 1 dose of MenC Vaccine administered to healthy infants at 2 to 6 months of age and as first, second or third dose in the second year of life,as measured by rBCA.
Time frame: Overall study period
Evaluation and comparison of antibody response and its persistence in terms of GMT and percent responders, as measured by rBCA.
Time frame: Overall study period
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novartis Vaccines